Similarly, a bi-specific aptamer targeting CD16α and c-Met was shown to recruit NK cells to c-Met-positive tumors and induce the production of CD16α which is an essential part of antibody-dependent cellular cytotoxicity (ADCC), thereby enhancing anti-tumor immunity [75]. The gene discussed is MET; the disease is neoplasm.